SHORT HILLS, N.J.--(BUSINESS WIRE)--Bayshore Pharmaceuticals, LLC is pleased to introduce three new FDA-approved products to their expanding portfolio.
Ipca Laboratories Limited's wholly owned subsidiary, Ipca Pharmaceuticals, Inc., USA has acquired, further 20% share capital of Bayshore Pharmaceuticals LLC, a New Jersey limited liability company for cash at US$ 1.2 millions.
Enforcement Report - Week of September 2, 2020
Bayshore Pharma Issues Voluntary Nationwide Recall of Metformin HCL ER Tablets
Bayshore Pharms` Generic Ketotifen Fumarate Receives Approval in US
Bayshore Pharms` Generic Pindolol Receives Approval in US
Bayshore Pharms's Generic Atropine Sulfate; Diphenoxylate Hydrochloride Receives Approval in US
In collaboration with Beximco Pharmaceuticals Ltd. (Dhaka, Bangladesh), Bayshore Pharmaceuticals announces that it has commercially launched Carvedilol tablets (3.125 mg, 6.25 mg, 12.5 mg, 25 mg). This launch represents the first prescription pharmaceutical product manufactured and approved in Bangladesh and was commemorated at a ceremony in Dhaka attended by the U.S. Ambassador to Bangladesh, Ms. Marcia Bernicat, as well as several key Ministers of the Bangladesh government and Beximco Pharma's Executive Management team.
APIs made by Laxachem Organics pvt ltd were not the source of bacteria in Pharmatech laxatives linked to a spate of Burkholderia cepacia infections according to the US Food and Drug Administration (FDA).